22.08.23|Sophie ShulmanThe pharmaceutical company has reached a compromise after being suspected of price-fixing with other generic drug manufacturers in the US. In the first four years, it will pay $22.5 million and in 2028 - $135 million. In addition, the company will donate two drugs worth $50 million to humanitarian organizations
22.11.22|Sophie ShulmanKare Schultz, who served as CEO of the pharmaceutical company for the past five years, has left the company a year early after amassing a salary of more than $100 million. His replacement, Richard Francis, is taking over with less debt and less legal issues, but with the big challenge of creating new growth engines
10.02.21|Reuters and CTech"We are positive towards contributing by manufacturing some of those vaccines that either have been approved or are just about to be approved," said CEO
10.02.21|Sophie ShulmanThe Israeli pharmaceutical company concluded the quarter with $4.5 billion in revenues, bringing it to a total of $16.6 billion for 2020
08.02.18|Dror ReichIsrael’s Teva reports a $17-billion goodwill impairment citing the decline of the U.S. generic market
11.09.17|Sophie Shulman, Dror ReichTroubled drugmaker says new CEO must work to quickly regain its financial credibility